Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Updated Appropriate Use Criteria for Amyloid and Tau PET : A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup

Rabinovici, Gil D. ; Knopman, David S. ; Arbizu, Javier ; Benzinger, Tammie L.S. ; Donohoe, Kevin J. ; Hansson, Oskar LU orcid ; Herscovitch, Peter ; Kuo, Phillip H. ; Lingler, Jennifer H. and Minoshima, Satoshi , et al. (2025) In Journal of Nuclear Medicine 66. p.5-31
Abstract

The Alzheimer’s Association and the Society of Nuclear Medicine and Molecular Imaging convened a multidisciplinary workgroup to update appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develop AUC for tau PET. Methods: The workgroup identified key research questions that guided a systematic literature review on clinical amyloid/tau PET. Building on this review, the workgroup developed 17 clinical scenarios in which amyloid or tau PET may be considered. A modified Delphi approach was used to rate each scenario by consensus as “rarely appropriate,” “uncertain,” or “appropriate.” Ratings were performed separately for amyloid and tau PET as stand-alone modalities. Results: For amyloid PET, 7 scenarios were... (More)

The Alzheimer’s Association and the Society of Nuclear Medicine and Molecular Imaging convened a multidisciplinary workgroup to update appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develop AUC for tau PET. Methods: The workgroup identified key research questions that guided a systematic literature review on clinical amyloid/tau PET. Building on this review, the workgroup developed 17 clinical scenarios in which amyloid or tau PET may be considered. A modified Delphi approach was used to rate each scenario by consensus as “rarely appropriate,” “uncertain,” or “appropriate.” Ratings were performed separately for amyloid and tau PET as stand-alone modalities. Results: For amyloid PET, 7 scenarios were rated as appropriate, 2 as uncertain, and 8 as rarely appropriate. For tau PET, 5 scenarios were rated as appropriate, 6 as uncertain, and 6 as rarely appropriate. Conclusion: AUC for amyloid and tau PET provide expert recommendations for clinical use of these technologies in the evolving landscape of diagnostics and therapeutics for Alzheimer’s disease.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer disease, amyloid PET, appropriate use criteria, biomarkers, brain pathology, clinical care, cognitive impairment, dementia, diagnosis, early detection, memory disorders, molecular imaging, neuroimaging, neurology, PET, PET imaging, tau PET, therapeutic strategies, treatment
in
Journal of Nuclear Medicine
volume
66
pages
5 - 31
publisher
Society of Nuclear Medicine Inc.
external identifiers
  • pmid:39778970
  • scopus:105008583456
ISSN
0161-5505
DOI
10.2967/jnumed.124.268756
language
English
LU publication?
yes
additional info
Publisher Copyright: COPYRIGHT © 2025 by the Society of Nuclear Medicine and Molecular Imaging, Inc., and the Alzheimer’s Association.
id
2b0ad2f1-10a5-4e7f-aa64-51f939cd628f
date added to LUP
2025-12-30 14:30:25
date last changed
2026-01-08 09:27:57
@article{2b0ad2f1-10a5-4e7f-aa64-51f939cd628f,
  abstract     = {{<p>The Alzheimer’s Association and the Society of Nuclear Medicine and Molecular Imaging convened a multidisciplinary workgroup to update appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develop AUC for tau PET. Methods: The workgroup identified key research questions that guided a systematic literature review on clinical amyloid/tau PET. Building on this review, the workgroup developed 17 clinical scenarios in which amyloid or tau PET may be considered. A modified Delphi approach was used to rate each scenario by consensus as “rarely appropriate,” “uncertain,” or “appropriate.” Ratings were performed separately for amyloid and tau PET as stand-alone modalities. Results: For amyloid PET, 7 scenarios were rated as appropriate, 2 as uncertain, and 8 as rarely appropriate. For tau PET, 5 scenarios were rated as appropriate, 6 as uncertain, and 6 as rarely appropriate. Conclusion: AUC for amyloid and tau PET provide expert recommendations for clinical use of these technologies in the evolving landscape of diagnostics and therapeutics for Alzheimer’s disease.</p>}},
  author       = {{Rabinovici, Gil D. and Knopman, David S. and Arbizu, Javier and Benzinger, Tammie L.S. and Donohoe, Kevin J. and Hansson, Oskar and Herscovitch, Peter and Kuo, Phillip H. and Lingler, Jennifer H. and Minoshima, Satoshi and Murray, Melissa E. and Price, Julie C. and Salloway, Stephen P. and Weber, Christopher J. and Carrillo, Maria C. and Johnson, Keith A.}},
  issn         = {{0161-5505}},
  keywords     = {{Alzheimer disease; amyloid PET; appropriate use criteria; biomarkers; brain pathology; clinical care; cognitive impairment; dementia; diagnosis; early detection; memory disorders; molecular imaging; neuroimaging; neurology; PET; PET imaging; tau PET; therapeutic strategies; treatment}},
  language     = {{eng}},
  pages        = {{5--31}},
  publisher    = {{Society of Nuclear Medicine Inc.}},
  series       = {{Journal of Nuclear Medicine}},
  title        = {{Updated Appropriate Use Criteria for Amyloid and Tau PET : A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup}},
  url          = {{http://dx.doi.org/10.2967/jnumed.124.268756}},
  doi          = {{10.2967/jnumed.124.268756}},
  volume       = {{66}},
  year         = {{2025}},
}